Celestoderm-B With Garamycin

Celestoderm-B with garamycin: an effective combination remedy for the treatment of skin diseases

Celestoderm-B with garamicin is a combination product containing the glucocorticosteroid betamethasone and the antibiotic gentamicin. This drug is used to treat a variety of infected skin lesions, including dermatoses, allergic and eczematous skin diseases, acute non-allergic dermatitis, skin infections in psoriasis, exfoliative dermatitis and lichen planus.

Celestoderm-B with Garamycin is manufactured by various pharmaceutical companies, including Schering-Plough in the United States of America, India, Belgium and Labeau N.V. in Belgium. It is available as cream and ointment with varying concentrations of active ingredients.

The active substances of the drug - gentamicin and betamethasone - have properties that contribute to the effective treatment of skin infections. Gentamicin is a broad-spectrum antibiotic that fights bacterial infection, and betamethasone is a powerful corticosteroid that reduces inflammation and itching associated with skin diseases.

However, the use of Celestoderma-B with garamicin has some contraindications. It is not recommended to use the drug in case of hypersensitivity to its components, in the presence of chickenpox, skin tuberculosis, as well as in cases of vaccination and during breastfeeding. During pregnancy, the use of the drug is possible only in rare exceptional cases.

Some side effects may occur when Celestoderma-B is used with Garamycin, including burning, itching, irritation, dry skin, folliculitis, hypertrichosis, acne, and hypopigmentation. When used under occlusive dressings, maceration, skin atrophy, stretch marks and miliaria may occur. With prolonged use of the drug on large surfaces, systemic side effects may occur.

The interaction of Celestoderma-B with other drugs has not yet been studied, and there is no data on this issue. There is also no evidence of drug overdose.

When using Celestoderma-B with Garamycin in children, you must be careful. If signs of sensitization or irritation appear, treatment should be discontinued. If superinfection develops, the drug is discontinued and Please note that the information provided above is based on the knowledge available up until September 2021, and there may have been updates or new developments since then. It is always advisable to consult a healthcare professional or refer to the latest medical literature for accurate and up-to-date information.